Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

INTRODUCTION: To examine the utility of sequential versus dual add-on approaches in patients who have type 2 diabetes and inadequate glycemic control with metformin therapy alone, we characterized the efficacy and safety of dual therapy with dapagliflozin or saxagliptin added to metformin in the ope...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Ther
Asıl Yazarlar: Mathieu, Chantal, Catrinoiu, Doina, Ranetti, Aurelian Emil, Johnsson, Eva, Hansen, Lars, Chen, Hungta, Garcia-Sanchez, Ricardo, Iqbal, Nayyar, Celiñski, Aleksander
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2018
Konular:
Brief Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://ncbi.nlm.nih.gov/pubmed/29802530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0445-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller